tiprankstipranks
Trending News
More News >
Arecor Therapeutics PLC (GB:AREC)
:AREC
Advertisement

Arecor Therapeutics PLC (AREC) AI Stock Analysis

Compare
3 Followers

Top Page

GB:AREC

Arecor Therapeutics PLC

(LSE:AREC)

Rating:53Neutral
Price Target:
56.00p
▲(0.00%Upside)
Arecor Therapeutics PLC shows potential with strong technical momentum and positive corporate events, but ongoing financial challenges and an unattractive valuation score due to losses and lack of dividends weigh on the overall score. The company's strategic initiatives in R&D and executive confidence are promising, but caution is advised due to high volatility and financial instability typical of biotech firms.

Arecor Therapeutics PLC (AREC) vs. iShares MSCI United Kingdom ETF (EWC)

Arecor Therapeutics PLC Business Overview & Revenue Model

Company DescriptionArecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
How the Company Makes MoneyArecor Therapeutics PLC generates revenue through multiple streams. The company earns money by developing its proprietary drug formulations and licensing them to pharmaceutical companies, which pays Arecor for the rights to use its advanced formulation technology. Additionally, Arecor engages in partnerships and collaborations with other pharmaceutical and biotechnology firms, receiving milestone payments and royalties based on the success and commercialization of the partnered products. These partnerships are crucial as they provide funding for research and development, which is a significant part of its business model. Furthermore, the company may also generate income from grants and government funding aimed at supporting innovative healthcare solutions.

Arecor Therapeutics PLC Financial Statement Overview

Summary
Arecor Therapeutics PLC shows significant revenue growth but faces challenges with negative net income and EBIT, indicative of high operational costs and R&D expenses typical for a biotech company. The declining gross profit margin and ongoing cash flow issues emphasize the struggle for financial stability.
Income Statement
45
Neutral
Arecor Therapeutics PLC has shown significant revenue growth over the years, with a notable increase from 2022 to 2023. However, the company consistently reports negative net income and EBIT, which indicates operational challenges in maintaining profitability. Gross profit margin has significantly declined in 2023 from previous levels due to increasing costs. The negative EBIT and EBITDA margins highlight the ongoing struggle to generate positive operating income, characteristic of early-stage biotech firms focusing on R&D.
Balance Sheet
50
Neutral
The balance sheet reveals a strong equity position, with a significant portion of the total assets funded by stockholders' equity, reflected in the equity ratio. However, the company has a concerning debt-to-equity ratio and a shrinking asset base, which could pose risks if cash reserves continue to deplete without achieving profitability. Despite this, low debt levels suggest manageable leverage.
Cash Flow
40
Negative
Cash flow statements show negative operating and free cash flows, emphasizing heavy cash burn typical for biotech companies at this stage. While the company raised capital through financing activities, the continuous negative free cash flow growth rate flags sustainability concerns if the trend persists. The operating cash flow to net income ratio highlights a challenging conversion of revenue into cash.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue5.05M4.57M2.40M1.16M1.70M
Gross Profit1.54M4.57M2.06M1.16M1.70M
EBITDA-10.15M-8.39M-10.06M-6.27M-3.26M
Net Income-10.24M-8.55M-9.26M-6.17M-2.75M
Balance Sheet
Total Assets8.72M15.38M21.77M20.92M4.28M
Cash, Cash Equivalents and Short-Term Investments3.26M6.75M12.81M18.32M2.90M
Total Debt232.00K338.00K288.00K231.00K2.00M
Total Liabilities3.37M5.85M4.31M2.37M3.51M
Stockholders Equity5.35M9.53M17.45M18.55M773.79K
Cash Flow
Free Cash Flow-9.18M-5.99M-11.13M-5.52M-1.91M
Operating Cash Flow-9.15M-5.84M-10.78M-5.45M-1.86M
Investing Cash Flow1.72M6.52M-7.99M-68.00K-49.32K
Financing Cash Flow5.65M-180.00K5.16M20.93M1.77M

Arecor Therapeutics PLC Technical Analysis

Technical Analysis Sentiment
Positive
Last Price56.00
Price Trends
50DMA
45.93
Positive
100DMA
44.23
Positive
200DMA
55.45
Positive
Market Momentum
MACD
2.98
Negative
RSI
97.58
Negative
STOCH
85.94
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AREC, the sentiment is Positive. The current price of 56 is above the 20-day moving average (MA) of 50.00, above the 50-day MA of 45.93, and above the 200-day MA of 55.45, indicating a bullish trend. The MACD of 2.98 indicates Negative momentum. The RSI at 97.58 is Negative, neither overbought nor oversold. The STOCH value of 85.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AREC.

Arecor Therapeutics PLC Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
53
Neutral
£21.33M-137.62%10.50%-9.60%
51
Neutral
$7.30B0.27-62.71%2.44%15.02%0.60%
£10.34M
£11.62M-20.90%
47
Neutral
£23.02M-87.30%71.17%
£7.20M-302.41%
67
Neutral
£26.36M-2.91%-5.33%60.20%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:AREC
Arecor Therapeutics PLC
56.00
-36.50
-39.46%
GB:IMM
ImmuPharma
2.06
0.28
15.73%
GB:OPTI
OptiBiotix Health
11.25
-14.25
-55.88%
GB:SAR
Sareum Holdings
17.00
-13.00
-43.33%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
155.50
-354.50
-69.51%
GB:TRX
Tissue Regenix
35.50
-27.50
-43.65%

Arecor Therapeutics PLC Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Arecor Therapeutics Establishes Expert Advisory Board for Oral Peptide Delivery
Positive
Jul 14, 2025

Arecor Therapeutics has formed a new Scientific Advisory Board composed of world-renowned experts in oral drug delivery and peptide therapeutics. This board will provide crucial technical and strategic guidance as Arecor aims to develop a novel technology platform for the oral delivery of peptides, which could significantly improve bioavailability and address patient needs in markets like diabetes and obesity. The initiative underscores Arecor’s commitment to advancing oral peptide delivery, a challenge that has persisted for decades, with the potential to enhance patient compliance and reduce healthcare burdens.

Business Operations and Strategy
Arecor Therapeutics Grants New Share Options to Drive Growth
Positive
Jun 4, 2025

Arecor Therapeutics plc announced the grant of 295,000 options under its Long Term Incentive Plan and 239,600 options under its All Employee Share Ownership Plan. These options are part of the company’s strategy to incentivize its leadership and employees, with performance conditions tied to time and share price outperformance. This move is likely to strengthen employee commitment and align their interests with the company’s long-term growth objectives.

Shareholder MeetingsBusiness Operations and Strategy
Arecor Therapeutics Passes All AGM Resolutions, Strengthening Governance
Positive
Jun 2, 2025

Arecor Therapeutics plc announced the successful passage of all resolutions at its Annual General Meeting, with one resolution deemed redundant and bypassed. This outcome reinforces the company’s governance and operational strategies, potentially strengthening its position in the biopharmaceutical industry and providing reassurance to stakeholders.

Executive/Board Changes
Arecor Therapeutics Announces Board Change with Dr. Alan Smith’s Retirement
Neutral
Jun 2, 2025

Arecor Therapeutics plc announced the retirement of Dr. Alan E Smith from his role as a Non-Executive Director after over 17 years of service. Dr. Smith’s scientific and strategic guidance has been pivotal in advancing Arecor from its early stages to a clinical-stage company. His departure marks a significant change in the board, but the company remains confident in its future success as it continues to develop its promising pipeline of therapeutics.

Other
Arecor Executives Show Confidence with Share Purchases
Positive
May 21, 2025

Arecor Therapeutics plc announced that key executives, including Chair Andrew Richards, CEO Sarah Howell, and CSO Jan Jezek, have purchased ordinary shares in the company. This move signifies confidence in the company’s future prospects and may positively influence stakeholder perceptions, potentially strengthening Arecor’s position in the biopharmaceutical industry.

Product-Related AnnouncementsBusiness Operations and Strategy
Arecor Partners with Skye Bioscience to Enhance Obesity Treatment
Positive
May 19, 2025

Arecor Therapeutics has partnered with Skye Bioscience to develop an enhanced formulation of nimacimab, a CB1 inhibitor for obesity treatment, using Arecor’s Arestat™ technology. This collaboration underscores Arecor’s strategic focus on innovative medicine development and offers significant potential for future licensing opportunities, while addressing unmet needs in metabolic disease treatment.

Other
Arecor Chair Increases Stake with Share Purchase
Positive
May 14, 2025

Arecor Therapeutics plc announced that Andrew Richards, the Chair of the company, has purchased 35,000 ordinary shares at £0.4125 each, increasing his total beneficial interest to 286,611 shares, which represents 0.76% of the total voting rights. This transaction reflects a significant vote of confidence in the company’s future prospects and may positively influence stakeholder perceptions and market positioning.

Shareholder MeetingsFinancial Disclosures
Arecor Therapeutics Releases 2024 Annual Report and Announces AGM
Neutral
May 6, 2025

Arecor Therapeutics plc has released its Annual Report and Accounts for the year ending December 31, 2024, and announced its Annual General Meeting scheduled for June 2, 2025. This announcement provides shareholders with updated financial information and strategic insights, potentially impacting investor confidence and the company’s market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025